Mosaic Therapeutics – an oncology therapeutics company dedicated to resolving cancer’s complexity to power new treatments for patients – announced the closing of its $28 million series A funding round. And Mosaic Therapeutics also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The funding was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital.
Mosaic’s use of advanced computational methods – while combining mining of large datasets with experimental approaches to identify and develop novel targeted therapies – completely reinvents the traditional approach to target and drug discovery. And the company’s bespoke relationship with the Wellcome Sanger Institute provides it with unique access to deep scientific expertise, infrastructure, and biological assets.
Brian Gladsden joins Mosaic as CEO following a 25-year career in biopharmaceuticals, including five years with Bayer AG and fifteen years with Novartis Oncology where he was Senior Vice President and a member of the Worldwide Leadership Team with responsibility for global commercialization and strategy for the portfolio. Gladsden has held various leadership positions, including country CEO, leading cancer therapeutic development and commercial launch across the US, Europe, Australia, South Korea and Japan.
Mosaic’s proprietary platform applies research from co-founder Dr. Mathew Garnett’s Translational Cancer Genomics Laboratory at the Wellcome Sanger Institute. And Dr. Garnett is a Senior Group Leader at Sanger with over 20 years experience in genomics and cancer therapeutics with past achievements including the co-discovery of BRAF mutations in cancer and Werner Syndrome helicase as a target in MSI tumors.
Alongside Dr. Garnett, the company was co-founded by Professor Emile Voest and Dr Adrian Ibrahim. And Professor Voest is Professor of Medical Oncology, Chairman of the Board of Cancer Core Europe, Group Leader at the Netherlands Cancer Institute and Oncode Institute, and Independent Director of the Board of Sanofi S.A. Dr. Ibrahim was formerly Head of Technology Translation at the Wellcome Sanger Institute, has 30 years experience across the discovery and development of cancer and genomics technologies, and has been involved in multiple genomics company spin-outs.
Mosaic is the most recent spin-out company from the Wellcome Sanger Institute, which is a world leader in genome research with notable achievements including being the single largest contributor to the Human Genome Project, co-founding the International Cancer Genome Consortium, and identifying specific BRAF mutations that underpinned a new class of transformational targeted cancer therapeutics.
What the funding will be used for: The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programs through preclinical development to IND-enabling studies. And the funds will also support recruitment efforts, building the Company’s senior leadership, experimental biology, and computational teams.
KEY QUOTES:
“I believe that Mosaic is ideally positioned to resolve the complexity of cancer, to discover and develop targeted therapies that address areas of high unmet need. The people, platform, connection to a world-leading genomics research institute, and strong investor partnerships are truly best in class.”
“To receive funding from such high caliber investors is testament to the potential of Mosaic’s technology and multidisciplinary team, as well as the exceptional support provided by the Wellcome Sanger Institute.”
— Brian Gladsden, CEO, Mosaic Therapeutics
“Mosaic is ready to lead the next wave of treatments for cancer, through the discovery of effective targeted therapies in molecularly-defined patients. Cancer is a complex disease and our platform, combining large-scale screening in advanced cancer models and cancer big data, gives Mosaic unprecedented clarity and insights. With high caliber investors, an experienced CEO, and solid scientific foundations, we’re building an exceptional team to deliver on our vision to develop safer and more effective medicines.”
— Dr Mathew Garnett, co-founder of Mosaic Therapeutics
“The unprecedented insights provided by the genomic revolution have enabled more targeted drug development, with drug targets being de-risked by genetics or data. This approach to drug discovery is a focus for us at Syncona and Mosaic is a great example of a company built around this concept. With a differentiated strategy that can accelerate entry to the clinic and the potential for application in a number of oncology settings in cancers which have previously been difficult to treat, we are excited for the potential of this platform. The opportunity for the Company, and most importantly for patients, is significant. I am thrilled that Brian has joined Mosaic to lead the next stage of the Company’s growth, and look forward to building this business in partnership with its world-class team.”
— Magdalena Jonikas, Lead Partner at Syncona Investment Management Limited and Director of Mosaic
“We are delighted to invest in Mosaic Therapeutics and its outstanding founders, backing our third spin-out from the Wellcome Sanger Institute. We also welcome Brian, a seasoned oncology executive, to the team. Mosaic’s unique combination of advanced data science, large dataset mining, and experimental approaches has the capability to identify and develop novel targeted therapies for the patient groups most likely to respond to these treatments. Cambridge (UK) is a globally important hub for biotechnology and life sciences, and Mosaic is a great example of innovation in the ecosystem.”
— Anne Horgan, Partner at Cambridge Innovation Capital and Director of Mosaic
